Impact of Alternative Ways to Operationalize Buprenorphine Treatment Duration on Understanding Continuity of Care for Opioid Use Disorder.
作者信息
Dong Huiru, Stringfellow Erin J, Russell W Alton, Bearnot Benjamin, Jalali Mohammad S
机构信息
MGH Institute for Technology Assessment, Harvard Medical School, Boston, MA, USA.
Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada.
出版信息
Int J Ment Health Addict. 2024 Aug;22(4):2285-2290. doi: 10.1007/s11469-022-00985-w.
Abstract
摘要
相似文献
1
Impact of Alternative Ways to Operationalize Buprenorphine Treatment Duration on Understanding Continuity of Care for Opioid Use Disorder.丁丙诺啡治疗时长的替代操作方式对理解阿片类物质使用障碍连续照护的影响
Int J Ment Health Addict. 2024 Aug;22(4):2285-2290. doi: 10.1007/s11469-022-00985-w.
2
Telehealth to improve continuity for patients receiving buprenorphine treatment for opioid use disorder.远程医疗改善接受丁丙诺啡治疗阿片类药物使用障碍患者的连续性。
Ann Fam Med. 2022 Apr 1;20(20 Suppl 1):2936. doi: 10.1370/afm.20.s1.2936.
3
Patient outcomes following buprenorphine treatment for opioid use disorder: A retrospective analysis of the influence of patient- and prescriber-level characteristics in Massachusetts, USA.丁丙诺啡治疗阿片类药物使用障碍后的患者结局：美国马萨诸塞州患者和处方医生层面特征影响的回顾性分析
Addiction. 2025 Jan;120(1):152-163. doi: 10.1111/add.16684. Epub 2024 Oct 13.
4
Multi-site intervention to improve emergency department care for patients who live with opioid use disorder: A quantitative evaluation.多地点干预措施改善阿片类药物使用障碍患者的急诊科护理：定量评估。
CJEM. 2020 Nov;22(6):784-792. doi: 10.1017/cem.2020.438.
5
Measurement Approaches to Estimating Methadone Continuity in Opioid Use Disorder Care.评估阿片类药物使用障碍治疗中美沙酮连续性的测量方法。
Med Care. 2023 May 1;61(5):314-320. doi: 10.1097/MLR.0000000000001838. Epub 2023 Mar 13.
6
Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers.出狱后治疗阿片类药物使用障碍的药物治疗连续性：一项基于社区的治疗提供者的定性研究。
Int J Drug Policy. 2022 Dec;110:103803. doi: 10.1016/j.drugpo.2022.103803. Epub 2022 Aug 11.
7
Relationship of hub and treatment characteristics with client outcomes in the initial Washington State hub and spoke cohort.华盛顿州首个枢纽与辐条式队列研究中枢纽及治疗特征与客户结局的关系。
J Subst Use Addict Treat. 2025 Jan;168:209544. doi: 10.1016/j.josat.2024.209544. Epub 2024 Oct 20.
8
Predictability of buprenorphine-naloxone treatment retention: A multi-site analysis combining electronic health records and machine learning.丁丙诺啡 - 纳洛酮治疗持续率的可预测性：一项结合电子健康记录和机器学习的多中心分析
Addiction. 2024 Oct;119(10):1792-1802. doi: 10.1111/add.16587. Epub 2024 Jun 24.
9
Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".先前的国家药物滥用治疗临床试验网络（CTN）阿片类药物使用障碍试验作为 NIDA CTN-0100“优化阿片类药物使用障碍药物治疗（RDD）的保留率、持续时间和停药策略”的背景和原理。
Addict Sci Clin Pract. 2021 Mar 6;16(1):15. doi: 10.1186/s13722-021-00223-z.
10
Teaching residents to prescribe buprenorphine for opioid use disorder: Insights from a community-based residency program.培训住院医师开具用于阿片类药物使用障碍的丁丙诺啡：来自一个社区住院医师项目的见解。
J Subst Abuse Treat. 2022 Jan;132:108621. doi: 10.1016/j.jsat.2021.108621. Epub 2021 Sep 14.
引用本文的文献
1
Prescription psychostimulant use, admissions and treatment initiation and retention in pregnant people with opioid use disorder.阿片类物质使用障碍孕妇使用处方精神兴奋剂、入院治疗及治疗起始与维持情况
Nat Ment Health. 2024 Jul;2(7):801-808. doi: 10.1038/s44220-024-00270-w. Epub 2024 Jun 11.
2
State-level racial and ethnic disparities in buprenorphine treatment duration in the United States.美国州级丁丙诺啡治疗时长方面的种族和族裔差异
Am J Addict. 2025 Jan;34(1):69-74. doi: 10.1111/ajad.13638. Epub 2024 Aug 6.
3
Application of an opioid use disorder cascade of care in a large public health system.在大型公共卫生系统中应用阿片类药物使用障碍护理级联。
Am J Drug Alcohol Abuse. 2024 Mar 3;50(2):181-190. doi: 10.1080/00952990.2024.2302500. Epub 2024 Feb 22.
本文引用的文献
1
Racial and Ethnic Disparities in Buprenorphine Treatment Duration in the US.美国丁丙诺啡治疗时长的种族和族裔差异
JAMA Psychiatry. 2023 Jan 1;80(1):93-95. doi: 10.1001/jamapsychiatry.2022.3673.
2
Association Between Buprenorphine Treatment Gaps, Opioid Overdose, and Health Care Spending in US Medicare Beneficiaries With Opioid Use Disorder.美沙酮维持治疗缺口、阿片类药物过量与美国医疗保险受益人群中阿片类药物使用障碍者的医疗保健支出之间的关联
JAMA Psychiatry. 2022 Dec 1;79(12):1173-1179. doi: 10.1001/jamapsychiatry.2022.3118.
3
Reducing opioid use disorder and overdose deaths in the United States: A dynamic modeling analysis.减少美国阿片类药物使用障碍和过量死亡人数：一项动态建模分析。
Sci Adv. 2022 Jun 24;8(25):eabm8147. doi: 10.1126/sciadv.abm8147.
4
Modeling the evolution of the US opioid crisis for national policy development.为国家政策制定模拟美国阿片类药物危机的演变。
Proc Natl Acad Sci U S A. 2022 Jun 7;119(23):e2115714119. doi: 10.1073/pnas.2115714119. Epub 2022 May 31.
5
Shifting Focus to Evidence-Based Management of Substance Use Disorders.将重点转向物质使用障碍的循证管理。
Ann Intern Med. 2022 May;175(5):753-754. doi: 10.7326/M22-0150. Epub 2022 Mar 22.
6
Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.阿片类激动剂治疗带药回家剂量增加与阿片类药物过量和治疗中断及停药的关系。
JAMA. 2022 Mar 1;327(9):846-855. doi: 10.1001/jama.2022.1271.
7
Challenges for Women Entering Treatment for Opioid Use Disorder.女性进入阿片类药物使用障碍治疗所面临的挑战。
Curr Psychiatry Rep. 2020 Oct 31;22(12):76. doi: 10.1007/s11920-020-01201-z.
8
Trends in Buprenorphine Treatment in the United States, 2009-2018.2009-2018 年美国丁丙诺啡治疗趋势。
JAMA. 2020 Jan 21;323(3):276-277. doi: 10.1001/jama.2019.18913.
9
Perinatal Depression in Low-Income Women: A Literature Review and Innovative Screening Approach.低收入妇女围产期抑郁：文献回顾与创新筛查方法。
Curr Psychiatry Rep. 2020 Jan 7;22(1):1. doi: 10.1007/s11920-019-1126-9.
10
Review: Sex-Based Differences in Treatment Outcomes for Persons With Opioid Use Disorder.综述：阿片类药物使用障碍患者治疗结局的性别差异。
Am J Addict. 2019 Jul;28(4):246-261. doi: 10.1111/ajad.12921. Epub 2019 May 26.
Zotero 插件